NEW YORK, July 19, 2017 -- According to a new market research report “Global Scar Treatment Market Size, Share, Development, Growth and Demand Forecast to 2023 - Industry Insight by Type of Treatment (Injectable, Invasive Surgical) by Type of Scars (Post-surgical, Acne, Keloid & Hypertrophic, Contracture, Stretch Marks) and by End User (Hospital, Private Clinic, Pharmacy & Drug store and E-commerce)” published by P&S Market Research, the global scar treatment market is expected to grow at a CAGR of 10.0% during 2017 - 2023.
Browse Detailed Information on Global Scar Treatment Market at: https://www.psmarketresearch.com/market-analysis/scar-treatment-market
According to the study, the global scar treatment market is likely to grow significantly during the forecast period, due to increasing prevalence of skin diseases such as psoriasis, eczema, vitiligo and photoaging of skin, which is increasing due to excessive exposure to pollution and ultraviolet radiation. This further results in sunburns, reduced skin elasticity, and hair loss. Skin diseases are also caused by various other factors, such as excessive alcohol consumption, environmental pollution, and consumption of tobacco. These conditions without proper treatment on time, can lead to the formation of scars. Various other skin problems such as, acne, burns, post-surgical marks, and stretch marks due to pregnancy or changes in body weight can also lead to scar formation. However, side effects of scar treatment products and therapies and high cost associated with scar treatment are some of the key factors restraining the growth of global scar treatment market.
Geographically, North America was the largest market for scar treatment in 2016 and is expected to contribute 40.5% by 2023. This dominant position of the region is primarily attributable to high disposable income, which further increases spending on personal care products. Moreover, the increasing appearance consciousness among the population in the region has also led to a rise in the adoption of technologically advanced scar treatment products.
Enquiry Before Purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=scar-treatment-market
According to the AAD, approximately 85% of the population in the U.S. suffers from acne, every year. The growing awareness about various technologies, which can enhance physical appearance of an individual is driving the demand for advanced scar treatment products in the U.S. The Asian scar treatment market is expected to grow at a faster rate as compared to the other regions, owing to growing focus on personal well-being, increasing disposable income and rising prevalence of skin related problems in the region.
Key players in the scar treatment market are collaborating and acquiring other players to offer more advanced solutions for scar treatment. In March 2017, Valeant Pharmaceutical International, Inc. announced the sale of its AcneFree, AMBI and CeraVe skincare brands to L’Oréal for $1.3 billion in cash. The transaction is expected to help the company to repay term loan debt under its senior credit facility.
Some of the other key players in the global scar treatment market are Smith & Nephew Plc, Syneron Medical Ltd., Mölnlycke Health Care AB, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Beijing Toplaser Technology Company Ltd., Merz GMBH & Co KGAA, Valeant Pharmaceuticals International Inc., Pacific World Corporation, Avita Medical Ltd. Enaltus LLC, Sonoma Pharmaceuticals Inc., CCA Industries Inc., Scarguard Labs LLC, Quantum Health, Hologic Inc.
About P&S Market Research
P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.
With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.
Contact:
Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google Plus | Facebook


Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
FDA Approves Mitapivat for Anemia in Thalassemia Patients
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



